H.R. 3433 · 118th Congress

Give Kids a Chance Act of 2024

Introduced on May 17, 2023 by Michael T. McCaul (R-TX-10). 235 cosponsors, 137 of them from another party. Latest action (Sep 24, 2024): Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Stage
Passed one chamber
Introduced
May 17, 2023
Cosponsors
235
137 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.

Subjects

  • Cancer
  • Child health
  • Congressional oversight
  • Drug safety, medical device, and laboratory regulation
  • Drug therapy
  • Government studies and investigations
  • Medical research
  • Prescription drugs

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Michael T. McCaulR-TX-10Sponsor

Democrats · 137

Republicans · 98

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. May 17, 2023Introduced in House
  2. May 17, 2023Introduced in House
  3. May 17, 2023 · HouseReferred to the House Committee on Energy and Commerce.
  4. May 19, 2023 · HouseReferred to the Subcommittee on Health.
  5. May 16, 2024 · HouseSubcommittee Consideration and Mark-up Session Held
  6. May 16, 2024 · HouseForwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 16 - 11.
  7. Sep 18, 2024 · HouseCommittee Consideration and Mark-up Session Held
  8. Sep 18, 2024 · HouseOrdered to be Reported (Amended) by the Yeas and Nays: 43 - 0.
  9. Sep 20, 2024Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-700.
  10. Sep 20, 2024 · HouseReported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-700.
  11. Sep 20, 2024 · HousePlaced on the Union Calendar, Calendar No. 594.
  12. Sep 23, 2024 · HouseMr. Bucshon moved to suspend the rules and pass the bill, as amended.
  13. Sep 23, 2024 · HouseConsidered under suspension of the rules. (consideration: CR H5582-5587)
  14. Sep 23, 2024 · HouseDEBATE - The House proceeded with forty minutes of debate on H.R. 3433.
  15. Sep 23, 2024Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5582-5585)
  16. Sep 23, 2024 · HouseOn motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5582-5585)
  17. Sep 23, 2024 · HouseMotion to reconsider laid on the table Agreed to without objection.
  18. Sep 24, 2024 · SenateReceived in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA10 reports
    $37.4M reported (all issues)
  2. EVERYLIFE FOUNDATION FOR RARE DISEASES5 reports
    $100K reported (all issues)
  3. ACADIA PHARMACEUTICALS4 reports
    $730K reported (all issues)
  4. GSK (fka GLAXOSMITHKLINE INC.)4 reports
    $4.8M reported (all issues)
  5. NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)4 reports
    $5.7M reported (all issues)
  6. NOVARTIS CORPORATION4 reports
    $6M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  7. The Leukemia & Lymphoma Society4 reports
    $1M reported (all issues)
  8. Patients Rising Now3 reports
    $30K reported (all issues)
  9. STEALTH BIOTHERAPEUTICS INC.3 reports
    $120K reported (all issues)
  10. BIOTECHNOLOGY INNOVATION ORGANIZATION2 reports
    $3.1M reported (all issues)
  11. BRIDGEBIO PHARMA INC.2 reports
    $500K reported (all issues)
  12. Bayer Corporation (consolidated report)2 reports
    $4.1M reported (all issues)
  13. HARMONY BIOSCIENCES, LLC2 reports
    $300K reported (all issues)Federal contractor: HARMONY BIOSCIENCES LLC$614.4K in contracts, FY2026AI match · 100%
  14. National Association of Pediatric Nurse Practitioners2 reports
    $48K reported (all issues)
  15. National Brain Tumor Society2 reports
    $40K reported (all issues)
  16. RARE DISEASE COMPANY COALITION2 reports
    $300K reported (all issues)
  17. SHIONOGI INC.2 reports
    $170K reported (all issues)Federal contractor: SHIONOGI INC$156.1M in contracts, FY2026AI match · 100%
  18. SPARK THERAPEUTICS, INC.2 reports
    $430K reported (all issues)
  19. St. Jude Children's Research Hospital2 reports
    $40K reported (all issues)Federal contractor: ST JUDE CHILDREN'S RESEARCH HOSPITAL INC$12.3M in contracts, FY2026AI match · 100%
  20. The Nemours Foundation - a Florida not-for-profit Corporation2 reports
    $389.1K reported (all issues)
  21. American Society of Nephrology1 report
    $80K reported (all issues)Federal contractor: AMERICAN SOCIETY OF NEPHROLOGY INCAI match · 100%
  22. AstraZeneca Pharmaceuticals LP1 report
    $640K reported (all issues)Federal contractor: ASTRAZENECA PHARMACEUTICALS LP$500 in contracts, FY2026AI match · 100%
  23. CHIESI USA, INC.1 report
  24. INCYTE CORPORATION1 report
    $350K reported (all issues)

Reports filed in 2023, 2024, 2025.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.